Concentration-controlled zidovudine therapy

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 3, 1998, Pages 331-338

  Fletcher, Courtney V ^a   Acosta, Edward P ^b   Henry, Keith ^b   Page, Linda M ^b   Gross, Cynthia R ^b   Kawle, Sagar P ^b   Remmel, Rory P ^b   Erice, Alejo ^b   Balfour Jr , Henry H ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CELL LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-HIV AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; ZIDOVUDINE;

EID: 0031661729     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90182-5     Document Type: Article

References (22)

1. Shafer RW, Iversen AKN, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J Infect Dis 1995;172:70-8.
2. Fletcher CV, Balfour HH Jr. Variability in the serum concentrations of zidovudine. Pharmacotherapy 1996;16: 1154-8.
3. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986;83:8333-7.
4. Ho HY, Hitchcock MJM. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother 1989;33:844-9.
5. Gao WY, Agbaria R, Driscoll RJS, Mitsuya H. Divergent antiviral activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994;269:12633-8.
6. Blum MR, Liao SHT, Good SS, de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988;85(suppl 2a):189-94.
7. Mentré F, Escolano S, Diquet B, Golmard JL, Mallet A. Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationships to long term efficacy and toxicity. Eur J Clin Pharmacol 1993;45:398-407.
8. Fletcher CV, Henry WK, Noormohamed SE, Rhame FS, Balfour HH Jr. The effect of cimetidine and ranitidine administration with zidovudine. Pharmacotherapy 1995;15:701-8.
9. Noormohamed SE, Henry WK, Rhame FS, Balfour HH Jr, Fletcher CV. Strategies for control of zidovudine concentrations in serum. Antimicrob Agents Chemother 1995;39:2792-7.
10. Acosta EP, Henry K, Page LM, Erice A, Balfour HH Jr, Fletcher CV. Pharmacokinetics and safety of concentration-controlled zidovudine therapy. Pharmacotherapy 1997;17:424-30.
11. d' Argenio DZ, Schumitzky A, Wolf W. Simulation of linear compartment models with application to nuclear medicine kinetic modeling. Comput Methods Programs Biomed 1988;27:47-54.
12. Robbins BL, Rodman J, McDonald C, Srinivas RV, Flynn PM, Fridland A. Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. Antimicrob Agents Chemother 1994;38:115-21.
13. Division of AIDS. Division of AIDS table for grading severity of adult adverse experiences. Rockville (MD): National Institute of Allergy and Infectious Disease; 1996.
14. Mulder J, McKinney C, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
15. Japour AJ, Mayers DL, Johnson VA, Kuritzkes DR, Beckett LA, Arduino JM, et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother 1993;37:1095-101.
16. Bolton S. Pharmaceutical statistics: Practical and clinical applications. 2nd ed. New York (NY): Marcel Dekker; 1990.
17. Pocock SJ. Clinical trials, a practical approach. New York: Wiley; 1983.
18. Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR [see comments]. Science 1993;259:1749-54.
19. Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, Melroe H, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996;274:985-9.
20. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6.
21. Saksela K, Stevens CE, Rubenstein P, Taylor PE, Baltimore D. HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann Intern Med 1995;123:641-8.
22. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team [see comments]. N Engl J Med 1997;337:725-33.